Benjamin P. Blumel

Array ( [id] => 16704369 [patent_doc_number] => 10954289 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2021-03-23 [patent_title] => Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments [patent_app_type] => utility [patent_app_number] => 17/021286 [patent_app_country] => US [patent_app_date] => 2020-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 17 [patent_no_of_words] => 45362 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17021286 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17858564 [patent_doc_number] => 11439702 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-13 [patent_title] => Influenza peptides and compositions [patent_app_type] => utility [patent_app_number] => 17/013000 [patent_app_country] => US [patent_app_date] => 2020-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 12 [patent_no_of_words] => 18504 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 272 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17013000 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16671389 [patent_doc_number] => 20210060152 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-04 [patent_title] => MULTIPLE MOSQUITO-BORNE FLAVIVIRUS VACCINE AND USE THEREOF IN INDUCING NEUTRALIZING ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/011140 [patent_app_country] => US [patent_app_date] => 2020-09-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1919 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17011140 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16720110 [patent_doc_number] => 20210087257 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-25 [patent_title] => HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/011934 [patent_app_country] => US [patent_app_date] => 2020-09-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24038 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17011934 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17865408 [patent_doc_number] => 20220288143 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING VACCINIA VIRUS AND GRANULOPOIESIS INHIBITOR AS ACTIVE INGREDIENTS [patent_app_type] => utility [patent_app_number] => 17/638750 [patent_app_country] => US [patent_app_date] => 2020-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19690 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17638750 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16511623 [patent_doc_number] => 20200390880 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-17 [patent_title] => Filovirus Consensus Antigens, Nucleic Acid Constructs And Vaccines Made Therefrom, And Methods Of Using Same [patent_app_type] => utility [patent_app_number] => 17/004818 [patent_app_country] => US [patent_app_date] => 2020-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25695 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 324 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17004818 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17665533 [patent_doc_number] => 11359214 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-14 [patent_title] => Simian (gorilla) adenovirus or adenoviral vectors and methods of use [patent_app_type] => utility [patent_app_number] => 17/002064 [patent_app_country] => US [patent_app_date] => 2020-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13783 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17002064 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16506433 [patent_doc_number] => 20200385689 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-10 [patent_title] => SCALABLE PRODUCTION METHOD FOR AAV [patent_app_type] => utility [patent_app_number] => 16/998548 [patent_app_country] => US [patent_app_date] => 2020-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7834 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16998548 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16756602 [patent_doc_number] => 10975139 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2021-04-13 [patent_title] => Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments [patent_app_type] => utility [patent_app_number] => 16/996297 [patent_app_country] => US [patent_app_date] => 2020-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 17 [patent_no_of_words] => 45397 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16996297 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18281618 [patent_doc_number] => 20230097090 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-30 [patent_title] => IMPROVED LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS [patent_app_type] => utility [patent_app_number] => 17/634516 [patent_app_country] => US [patent_app_date] => 2020-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 65190 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -63 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17634516 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17400895 [patent_doc_number] => 20220042985 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => SARS-CoV-2 IgG/IgM ANTI-BODY DETECTION KIT [patent_app_type] => utility [patent_app_number] => 16/987049 [patent_app_country] => US [patent_app_date] => 2020-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5047 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16987049 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18116384 [patent_doc_number] => 11547756 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-10 [patent_title] => Method of treating influenza A [patent_app_type] => utility [patent_app_number] => 16/984827 [patent_app_country] => US [patent_app_date] => 2020-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 23376 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16984827 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17805915 [patent_doc_number] => 20220257750 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-18 [patent_title] => PROTEOLYSIS-TARGETING VIRUS, LIVE VACCINE THEREOF, PREPARATION METHOD AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/624822 [patent_app_country] => US [patent_app_date] => 2020-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12604 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17624822 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16336556 [patent_doc_number] => 10787501 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2020-09-29 [patent_title] => Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments [patent_app_type] => utility [patent_app_number] => 16/912678 [patent_app_country] => US [patent_app_date] => 2020-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 17 [patent_no_of_words] => 45364 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16912678 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16948411 [patent_doc_number] => 20210207102 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-08 [patent_title] => VIRUS-LIKE PARTICLES CO-EXPRESSING TOXOPLASMA GONDII IMC, ROP18, AND MIC8, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME [patent_app_type] => utility [patent_app_number] => 16/901705 [patent_app_country] => US [patent_app_date] => 2020-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12590 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16901705 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16466807 [patent_doc_number] => 20200368344 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-26 [patent_title] => CHIKV RNA VACCINES [patent_app_type] => utility [patent_app_number] => 16/898268 [patent_app_country] => US [patent_app_date] => 2020-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 70414 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16898268 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18503630 [patent_doc_number] => 11701420 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-07-18 [patent_title] => Parenteral norovirus vaccine formulations [patent_app_type] => utility [patent_app_number] => 16/894291 [patent_app_country] => US [patent_app_date] => 2020-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 21 [patent_no_of_words] => 17462 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16894291 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17134833 [patent_doc_number] => 11136379 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-05 [patent_title] => Binding molecules directed against influenza hemagglutinin and uses thereof [patent_app_type] => utility [patent_app_number] => 16/946092 [patent_app_country] => US [patent_app_date] => 2020-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 27971 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16946092 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17748260 [patent_doc_number] => 20220226463 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-21 [patent_title] => RECOMBINANT NON-STRUCTURAL PROTEIN 1, RECOMBINANT INFLUENZA VIRUS AND IMMUNOLOGICAL COMPOSITION INCLUDING THE SAME, AND METHOD OF TREATING OR PREVENTING DISEASE OR CONDITION CAUSED BY OR ASSOCIATED WITH INFLUENZA VIRUS [patent_app_type] => utility [patent_app_number] => 17/616583 [patent_app_country] => US [patent_app_date] => 2020-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9061 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17616583 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18036195 [patent_doc_number] => 20220380410 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-01 [patent_title] => Live Attenuated Universal Influenza Virus Vaccines, Methods and Uses Thereof [patent_app_type] => utility [patent_app_number] => 17/616137 [patent_app_country] => US [patent_app_date] => 2020-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20116 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17616137 [rel_patent_id] =>[rel_patent_doc_number] =>)